Skip to content

Regional COVID Epidemiology in England (RECEDE)

Regional Epidemiology of COVID-19 and Acute Kidney Injury in England

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04579562
Acronym
RECEDE
Enrollment
5000
Registered
2020-10-08
Start date
2020-11-01
Completion date
2021-10-31
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

The COVID-19 pandemic has exposed the unwanted variation in outcomes as evidence by Public Health England's report on increased mortality in regions of the country. For example, UHDB, in East Midlands, has reported a high crude mortality as compared to other Trusts in the region.8 There may also have been variation in the incidence of complications of COVID-19 in the form of AKI, which may have influenced mortality. Variation in outcomes may be because of various factors - differing population demographics, underlying health conditions in the population, deprivation, physician preference and knowledge and ethnic diversity. Unwanted variation is care that is not consistent with a patient's preference or related to \[their\] underlying illness. It is important to understand the reason for unwanted variation in outcomes associated with COVID-19 to minimise patient harm and reduce morbidity and mortality.

Interventions

OTHERNo intervention

This is observational, non-interventional study

Sponsors

University Hospitals of Derby and Burton NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

This study will have two work packages (WP). Work Package 1 (WP1): Regional epidemiology of COVID-19 in England All patients who are admitted to hospital with COVID-19 infection between 1st March 2020 and 30th June 2020 and who meet following criteria will be included 1. Diagnostic code for COVID-19 (U07.1) in any of the 20 diagnoses codes 2. Adult patients greater or equal to 18 years of age. Work Package 2 (WP2): Epidemiology of COVID-19 associated AKI in England All patients who are admitted to hospital with acute kidney injury (AKI) between 1st March 2020 and 30th June 2020 and who meet following criteria will be included 1. Diagnostic code for AKI (N17) in any of the 20 diagnoses codes 2. Adult patients greater or equal to 18 years of age.

Exclusion criteria

WP1: The following patients will be excluded from the study 1. Patients not admitted to the hospital 2. Paediatric patients \< 18 years of age WP2: The following patients will be excluded from the study 1. Patients not admitted to the hospital 2. Paediatric patients \< 18 years of age 3. Patients on chronic maintenance haemodialysis or peritoneal dialysis

Design outcomes

Primary

MeasureTime frameDescription
All-cause mortality30 daysIn-hospital all cause mortality in patients with acute kidney injury and COVID-19
acute kidney injury30 daysIncidence of acute kidney injury in patients with COVID-19

Secondary

MeasureTime frameDescription
Mechanical ventilation30 daysNeed for mechanical ventilation in patients with COVID-19

Contacts

Primary ContactNitin V Kolhe, DM
nitin.kolhe@nhs.net01332788266

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026